Adrian Haigh Sells 22,223 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh sold 22,223 shares of the firm’s stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $9.32, for a total transaction of $207,118.36. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Adrian Haigh also recently made the following trade(s):

• On Friday, April 19th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $9.34, for a total value of $207,553.48.
• On Wednesday, April 17th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $9.91, for a total transaction of $220,220.02.
• On Monday, April 15th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $10.30, for a total transaction of $228,886.60.

Fennec Pharmaceuticals Stock Performance

Shares of NASDAQ:FENC opened at $9.24 on Wednesday. The stock’s 50-day simple moving average is $10.05 and its two-hundred day simple moving average is $9.42. The stock has a market capitalization of $250.40 million, a price-to-earnings ratio of -15.15 and a beta of 0.38. Fennec Pharmaceuticals Inc has a 52-week low of $6.30 and a 52-week high of $11.92.

Fennec Pharmaceuticals (NASDAQ:FENC) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). The company had revenue of $9.74 million for the quarter, compared to the consensus estimate of $9.47 million. As a group, equities analysts forecast that Fennec Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.

Institutional Trading of Fennec Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC grew its stake in shares of Fennec Pharmaceuticals by 107.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,048 shares of the company’s stock valued at $34,000 after acquiring an additional 1,578 shares during the period. Allspring Global Investments Holdings LLC purchased a new position in Fennec Pharmaceuticals during the third quarter valued at approximately $50,000. Jump Financial LLC bought a new position in shares of Fennec Pharmaceuticals in the fourth quarter worth approximately $158,000. Eudaimonia Advisors LLC increased its stake in Fennec Pharmaceuticals by 90.8% in the 4th quarter. Eudaimonia Advisors LLC now owns 32,686 shares of the company’s stock worth $367,000 after buying an additional 15,556 shares in the last quarter. Finally, Hartford Financial Management Inc. raised its stake in Fennec Pharmaceuticals by 4.4% during the 4th quarter. Hartford Financial Management Inc. now owns 47,348 shares of the company’s stock valued at $531,000 after purchasing an additional 2,000 shares during the period. Institutional investors own 55.51% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on FENC shares. Craig Hallum lifted their price objective on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, March 18th. Wedbush restated an “outperform” rating and set a $16.00 price objective on shares of Fennec Pharmaceuticals in a research report on Monday, March 18th. Finally, HC Wainwright lifted their target price on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Thursday, April 4th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.